You are right, it leads to selective pressure leading to resistance.
Similarly it can happen with the most crucial antimicrobial agents such as carbapemens. There is increasing incidence of imipenem-resistant Pseudomonas strains associated with the extremely high rate of use of this antibiotic, which might have resulted in high selective pressure on those microorganisms.
Excessive use of these antibiotics leads to selective pressure on the microorganisms and render them resistant to these drugs.
This is major contributory factor for increased incidence of ESBL's and now MBL's too, as is told by Dr.Godfred.
You can go through these articles:
P. Reddy, M. Malczynski, A. Obias, S. Reiner, N. Jin, J. Huang, G. A. Noskin, and T. Zembower. Screening for Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae among High-Risk Patients and Rates of Subsequent Bacteremia
Clin Infect Dis. (2007) 45 (7): 846-852
Fennell J, Vellinga A, Hanahoe B, Morris D, Boyle F, Higgins F, Lyons M, O'Connell K, Keady D, Cormican M. Increasing prevalence of ESBL production among Irish clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC Infect Dis. 2012 May 15;12:116
Rishi H.-P. Dhillon and John Clark, “ESBLs: A Clear and Present Danger?,” Critical Care Research and Practice, vol. 2012
Dear Peter and Godfred, It is indeed an important point about Ceftiofur and further research has to be pursued in this direction particularly in this region (Middle east) and its relevance in ESBL.